Search the Newsreel

Deep Track group reports 3.25% Viridian Therapeutics (VRDN) ownership in latest filing

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have jointly reported a 3.25% ownership stake in Viridian Therapeutics (VRDN). This ownership, totaling 3,592,740 shares, is held with shared voting and dispositive power. The filing is based on 110,427,682 shares …

Virinchi Q1 FY27 Results: Revenue Rs 70 Cr, Swings to Net Loss Rs 2 Cr

Virinchi consolidated net profit rises 11.63% in the June 2026 quarter

Trading the Move, Not the Narrative: (VRDN) Edition

This article provides an AI-generated analysis for Viridian Therapeutics Inc. (NASDAQ: VRDN), highlighting mixed sentiment and choppy conditions across different time horizons. It presents three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, along with multi-timeframe signal …

Viridian Therapeutics, Inc. Stock 12‑Month Price Target Cut to $36.07, Implies 58% Upside

The average 12-month price target for Viridian Therapeutics, Inc. (VRDN) stock has been lowered to $36.07 from $36.81 by 15 analysts, suggesting a potential upside of approximately 58% from its August 12 closing price. Despite the target cut, the consensus rating from 17 covering …

Analysts Have Just Cut Their Viridian Therapeutics, Inc. (NASDAQ:VRDN) Revenue Estimates By 22%

Analysts have significantly revised down Viridian Therapeutics' 2026 revenue estimates by 22% to US$22 million, representing a 70% reduction from the past 12 months. Concurrently, per-share loss forecasts have increased to US$3.97. Despite a recent 10% stock price increase, the updated consensus suggests a …

VRDN Stock Records Biggest Single Day Gains In 45 Months – And It’s Not Just Due To A Better-Than-Feared Q1 Loss

NVRI Stock Price and Chart — NYSE:NVRI

This article provides a comprehensive overview of Enviri Corporation (NVRI) stock performance, financial data, and analyst ratings. It details key statistics like market capitalization, recent earnings, and sector information, alongside historical price movements and future forecasts. The company's business segments, Harsco Environmental and Harsco …

Enviri Corp (NVRI) (Q2 2026) Earnings Call Highlights: Strategic Contract Exits and ...

Enviri Corp (NVRI) reported Q2 2026 results including $187 million in total revenue and adjusted EBITDA of $34 million, a 22% increase year-over-year. The company's strategic exit from two major rail contracts, impacting revenue by $136 million, is expected to de-risk operations and improve …

Enviri Corp 2026: Revenue $187.34M, EPS ($14.21) — 10-Q Summary

Enviri Corp reported its 2026 financial results, showing a significant decline in revenue to $187.34M and a net loss of ($394.51M), resulting in a diluted loss per share of ($14.21). These results reflect substantial charges and contract-exit activities, particularly following the spin-off of Clean …

Enviri Corporation (NYSE: NVRI) takes $207M rail exit hit, slashes debt

Enviri (NYSE:NVRI) Shares Down 7% Following Weak Earnings

Enviri Q2 Earnings Call Highlights

Key Points Interested in Enviri Corporation? Here are five stocks we like better. Enviri exceeded its second-quarter expectations: Adjusted EBITDA rose 22% year over year to $34 million, while Harsco Environmental delivered a 15% increase in adjusted EBITDA to $46 million. Rail benefited from …

Enviri Corporation 2026 Q2 - Results - Earnings Call Presentation (NYSE:NVRI) 2026-08-11

Enviri Corporation Q2 2026 Earnings Call Summary - Moby Strategic Pivot and Operational Performance Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. …

Enviri Corporation Q2 2026 Earnings Call Summary

Enviri Corporation Q2 2026 Earnings Call Summary - Moby Strategic Pivot and Operational Performance Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. …

Earnings call transcript: Enviri Q2 2026 profit trends improve as stock rises 4.9%

Enviri Corp. reported improved Q2 2026 core results after selling Clean Earth, with adjusted EBITDA up 22% to $34 million. Despite a reported adjusted loss of $0.63 per share due to unusual charges and negative revenue adjustments from exiting rail contracts, the company's stock …

Enviri (NYSE:NVRI) Releases Earnings Results, Misses Estimates By $0.32 EPS

Enviri Corp (NVRI) reported Q2 2026 results including $187 million in total revenue and adjusted EBITDA of $34 million, a 22% increase year-over-year. The company's strategic exit from two major rail contracts, impacting revenue by $136 million, is expected to de-risk operations and improve …

Enviri reports Q2 2026: $187M revenues, GAAP loss $297M from continuing ops, Adjusted EBITDA $34M

Enviri (NVRI) reported its second-quarter 2026 results, showing revenues from continuing operations of $187 million and a GAAP consolidated loss of $297 million. The company's Adjusted EBITDA for the quarter was $34 million, and it announced strategic exits from two European Rail ETO contracts …

Enviri exits Deutsche Bahn, Network Rail ETO contracts

* Enviri (NVRI [https://seekingalpha.com/symbol/NVRI]) said its Harsco Rail subsidiaries have concluded all activities under engineered-to-order (ETO) contracts with Deutsche Bahn and Network Rail. * Harsco Rail Europe agreed to sell the Deutsche Bahn contract assets, including inventory and intellectual property, to General Atomics subsidiary …

Virinchi shareholders approve Bristlecone Hospitals acquisition

Enviri ends stoneblower build, proposes longer-life fleet plan

Enviri (NYSE: NVRI) announced the conclusion of engineered-to-order contracts with Deutsche Bahn and Network Rail, leading to a noncash impairment charge of $75 million and an incremental liability of $133 million. Harsco Rail Europe sold assets and intellectual property to Gleisbaumechanik Brandenburg, while Harsco …

Is Viridian Therapeutics' (VRDN) Widening Losses Despite Higher Revenue Reframing Its Risk Reward Profile?

HC Wainwright Has Negative Forecast for VRDN Q3 Earnings

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Viridian Therapeutics (NASDAQ:VRDN) recently reported quarterly results showing revenues significantly better than expected, though statutory losses per share were in line with forecasts. Despite the strong revenue performance, analysts have subsequently cut their revenue outlook for 2026 and increased their loss per share expectations, …

Viridian Therapeutics (VRDN) Stock Rises Despite Deepening Losses And Cash Burn

RBC Adjusts Viridian Therapeutics PT to $36 From $35, Maintains Outperform Speculative Risk Rating

RBC has increased its price target for Viridian Therapeutics (VRDN) to $36 from $35, while reiterating an Outperform Speculative Risk rating. The company currently holds an average analyst rating of "buy" with a mean price target of $36.75.

Viridian Therapeutics (NASDAQ:VRDN) Issues Quarterly Earnings Results, Misses Expectations By $0.02 EPS

State Street Corporation (NASDAQ: VRDN) discloses 5.5% Viridian Therapeutics ownership

State Street Corporation has reported a 5.5% ownership stake in Viridian Therapeutics, Inc. (VRDN), held through various subsidiaries including State Street Global Advisors entities. This significant holding comprises 6,124,976 shares of common stock, with shared voting and dispositive power, indicating a notable institutional position …

Enviri Corp (NVRI) Earnings Forecast: Future EPS & Revenue Growth Estimates

Enviri Corp (NVRI) has an earnings forecast score of 7.33, placing it 93rd out of 159 in its industry. Analysts have set an average price target of $21.00, with a consensus indicating a "Buy" trend. The company's expected revenue for the next quarter is …

Truist Financial Issues Positive Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price

Viridian Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Viridian Therapeutics Inc has released its earnings summary for the quarter that concluded on June 30. The report details the company's financial performance during this period, providing key insights into its operational results. This information is available through Refinitiv, with additional access offered via …

Viridian Therapeutics 2Q 2026: Revenue $284K, EPS $(1.05) — 10-Q Summary

Viridian Therapeutics reported its second-quarter 2026 results, showing early commercial revenue of $284K following FDA approval of Veligrotug (Lumvoa). The company experienced a wider net loss of $127.1M, reflecting its transition from an R&D to a commercial organization. Key highlights include the U.S. launch …

Viridian Therapeutics to See 'Minimal' Revenue Growth in H2, RBC Capital Markets Says

RBC Capital Markets forecasts "minimal" revenue growth for Viridian Therapeutics (VRDN) in the second half of the year. The report, published by MT Newswires, indicates that a more meaningful inflection in revenue is expected after this period. Access to the full article requires a …